Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Address: 1106 Budapest, Keresztúri út 30-38. Hungary,Hungary
Tel: +36 1 265-5555
Web: http://www.egis.hu/Default.aspx
EGIS Pharmaceuticals PLC is one of the leading pharmaceutical companies in Central Europe. Our most important activities are the production of pharmaceuticals and active pharmaceutical ingredients, pharmaceutical research and development, sales of finished products and active pharmaceutical ingredients.
Out of our three production facilities, two are in Budapest. One of them is seated in our headquarters, in Keresztúri Street, where Active Pharmaceutical Ingredients are made, and the other is in Bökényföldi Street, with our tablet, injection and packaging plants as well as commercial warehouses.
In our third facility, in Körmend, tablets, ointments, suppositories, solutions, syrups and aerosols are made and packaged.
Our production system meets the international GMP principles and the regulations of the Hungarian National Institute of Pharmacy.
Production of Active Pharmaceutical Ingredients
Production of active pharmaceutical ingredients is an important field in the activity of EGIS PLC (and its legal predecessors). As a result of professional experience accumulated through the efforts of the last decades and the continuous modernization of the facilities, competitiveness of the production of active pharmaceutical ingredients has been maintained as it is well proved by successful exports and the good results of the national and international official controls.
At present, in this field of activity approximately 50 different active pharmaceutical ingredients and their intermediates are produced a year. The wide scale of products can be characterized by the gradual renewal and replacement of individual products.
Production of active pharmaceutical ingredients has been able to respond to the challenges of quality assurance and environment protection of the recent past successfully. Thorough grounding and commitment of people working in this strategic field are an important part of the complex professional culture belonging to EGIS.
Pharmaceutical Research and Development
Our research activity is aimed at the development of generic pharmaceutical products offering high marketing potential, the chemical synthesis of putative original drug molecules, and testing of their pharmacological effects. Our research work focuses on drugs effective on cardiovascular diseases, disorders of the central nervous system, the respiratory and digestive systems. At the end of our business year, closed on 30th September 2009, the number of our registrations and marketing authorizations totalled up to 2222.
Sales of Finished Products and Active Pharmaceutical Ingredients
EGIS PLC is ranked third on the basis of the number of packages sold in the Hungarian market, and is placed fifth concerning our sales revenue.
72% of our sales revenue comes from our export activity. We export our finished products first of all to the Eastern regions like Russia, Central- and Eastern-European countries, and the CIS countries. As for the Western countries France and the UK are among our main markets for finished products, while France, the Netherlands, Japan and the United States are considered as the greatest markets for our active ingredients and intermediate export.
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in…
Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance…
Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and…
Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient…
Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG…
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology…
See our Cookie Privacy Policy Here